

Company Overview

Ehave, Inc. is empowering the mental healthcare community with a next generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave's mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged. Ehave Connect is cloud-based and offers a powerful set of core features that integrate with a growing selection of tools and applications. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder. Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis through its collaboration with leading medical cannabis licensed producers. Ehave Connect improves patient outcomes by allowing parties together.

Select Financials and Facts

OTC Ticker:	EHVVF
Closing Price at 05/11/18:	\$0.04
52-Week Range:	\$0.03 - 0.17
Shares Outstanding (3/30/2018):	71.3 million
Market Capitalization (04/26/12):	\$2.75 million
Fiscal Year-end:	December 31
Average Volume (30 day)	159,944

Ehave Inc.
2020 Winston Park Drive, Suite 201
Oakville, ONT L6H 6X7 Canada
(905) 362-1499
ir@ehave.com

Investment Highlights

- Ehave could help solve North America's opioid crisis by helping medical professionals correctly diagnose and treat patients using safer, less addictive medicine, which could be marijuana or something else.
- Ehave's relationship with MedReleaf (TSE: LEAF) could potentially change the way physicians diagnose and prescribe patients medical marijuana, which is unchartered territory.
- MedReleaf is looking to Ehave to validate its cannabis therapies across multiple health conditions, especially mental health and pain conditions where treatment benefits can be difficult to ascertain.
- By using Ehave's cloud based platform, medical professionals will be able to make evidence based decisions while tracking and monitoring patients.
- Despite the fact that marijuana has proven to be beneficial for treating a wide range of medical conditions, professionals lack knowledge and therefore are hesitant to advise patients on treatment plans.
- The Journal of the American Board of Family Medicine conducted a survey with 520 family physicians responding. 92% of respondents believe continuing medical marijuana education should be available to family physicians. 81% agreed physicians should have formal training before recommending medical marijuana.
- Ehave's CEO, Prateek Dwivedi brings more than 20 years of tech and healthcare experience to the firm. He was a former VP and CIO at Mount Sinai Hospital in Toronto, where he led a 170+ person team responsible for technology infrastructure.
- Ehave currently has Collaboration Agreements with Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) and Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF), as well as a partnership with MedReleaf Corp. (TSE:LEAF) (OTC: MEDFF) to develop a branded MedReleaf app utilizing the Ehave Connect mental health informatics platform.
- Ehave has partnered with Multi-Health Systems to gain access to their library of mental health assessments to assist in the diagnostic process and in the development of intervention treatment plans. The Ehave platform also helps pharmaceutical developers by reducing errors, saving money, cutting time, and improving compliance.

For more information contact: David Kugelman (866) 692-6847

Market Opportunity

- By 2024, more than 450,000 Canadian patients will be prescribed medical cannabis, creating a market worth more than \$1.3 billion, according to Health Canada estimates
- Thousands of Canadians are federally licensed to possess and use medical marijuana anywhere in Canada under the Access to Cannabis for Medical Purposes Regulations which came into effect on August 24th 2016.
- Under Canada's Access to Cannabis for Medical Purposes Regulations program, the decision to use marijuana for medical purposes is now between the patient and physician alone. All medical documentation must be accessible from the physician, records department, walk in clinic or hospital.
- US investment banking firm Cowen & Co. expects the U.S. cannabis industry to generate \$75 billion in gross sales by 2030. Cowen also said, "The trends that we've historically seen for cannabis in the U.S. tend to be mirrored in Canada."

Competitive Advantage

Ehave leadership brings proven corporate, scientific, and software development expertise. The primary focus of Ehave management is on developing and delivering innovative products and services to improve the lives of persons living with mental health disorders. The Ehave platform allows medical professionals to record intake and assignment, assessment, treatment, outcomes verification, and ongoing management. Ehave works with trusted third-parties to integrate tools into their ecosystem so that clinicians can easily diagnose and treat patients while taking advantage of all the collected data.

Ehave works to validate cannabis therapies across multiple health conditions, especially mental health and pain conditions where treatment benefits can be difficult to ascertain.



The foregoing compilation relates to Ehave Inc. (OTC: EHVVF) and contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. When used in this document, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to Ehave Inc., or its management, are intended to identify such forward-looking statements. Ehave Inc.'s actual results, performance or achievements could differ materially from the results expressed in, or implied by these forward-looking statements. For more detailed information see Ehave Inc.'s Form 20-F and other related documents filed with the Securities and Exchange Commission. This does not constitute an offer to buy or sell securities by the Company and is meant purely for informational purposes. ATLCF was paid \$500 for the creation of this document by a third-party. All information in this report is from public sources provided by the Company, which, although believed to be reliable, cannot be guaranteed. This information is not an endorsement of the Company and the individuals who created this document are not responsible for any claims made by the Company. You should independently investigate and fully understand all risks before investing.